Three prognostic factors influence clinical outcomes of primary testicular lymphoma
详细信息 查看全文
- 作者：Yu Wang (1)
Zhi-Ming Li (1)
Jia-Jia Huang (1)
Yi Xia (1)
Heng Li (2)
Ya-Jun Li (1)
Ying-Jie Zhu (1)
Wei Zhao (1)
Xi-Ya Xia (1)
Wen-Xiao Wei (1)
Hui-Qiang Huang (1)
Tong-Yu Lin (1)
Wen-Qi Jiang (1) - 关键词：Primary testicular DLBCL ; Prognostic factors ; Rituximab treatment ; CNS prophylaxis
- 刊名：Tumor Biology
- 出版年：2013
- 出版时间：February 2013
- 年：2013
- 卷：34
- 期：1
- 页码：55-63
- 全文大小：363KB
- 参考文献：1. Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29:2766-2. CrossRef
2. Zouhair A, Herrmann E, Ugurluer G, et al. Primary testicular lymphoma. Swiss Med Wkly. 2010;140:w13076.
3. Gundrum JD, Mathiason MA, Moore DB, et al. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009;27:5227-2. CrossRef
4. Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study group. J Clin Oncol. 2003;21:20-. CrossRef
5. Mazloom A, Fowler N, Medeiros LJ. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma. 2010;51:1217-4. CrossRef
6. Linassier C, Desablens B, Lefrancq T, et al. Stage I–IIE primary non-Hodgkin’s lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group. Clin Lymphoma. 2002;3:167-2. CrossRef
7. Avilés A, Nambo MJ, Cleto S, et al. Rituximab and dose-dense chemotherapy in primary testicular lymphoma. Clin Lymphoma Myeloma. 2009;9:386-. CrossRef
8. Chan JK. The new World Health Organization classification of lymphomas: the past, the present and the future. Hematol Oncol. 2001;19:129-0. CrossRef
9. Anonymous. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329:987-4.
10. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored InternationalWorking Group. J Clin Oncol. 1999;17:1244.
11. Grillo-Lopez AJ, Cheson BD, Horning SJ, et al. Response criteria for NHL: importance of ‘normal-lymph node size and correlations with response rates. Ann Oncol. 2000;11:399-08. CrossRef
12. Shahab N. Testicular lymphoma. Semin Oncol. 1999;26:259-9.
13. Cao B, Ji DM, Zhou XY, et al. A clinical analysis of primary testicular diffuse large B-cell lymphoma in China. Hematology. 2011;16:291-. CrossRef
14. Sussman EB, Hajdu SI, Lieberman PH, Whitmore WF. Malignant lymphoma of the testis: a clinicopathologic study of 37 cases. J Urol. 1977;118:1004-.
15. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-7. CrossRef
16. Vitolo U, Ferreri AJ, Zucca E. Primary testicular lymphoma. Crit Rev Oncol Hematol. 2008;65:183-. CrossRef
17. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-2. CrossRef
18. Pfreundschuh M, Trümper L, Osterborg A. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-1. CrossRef
19. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of biweekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105-6. CrossRef
20. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027-3. CrossRef
21. Batchelor T, Leahy N, Kaufman D. High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin’s lymphoma. Clin Lymphoma. 2001;2:116-. discussion 120-. CrossRef
22. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102:4284-. CrossRef
23. Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol. 2011;90:809-8. CrossRef - 作者单位：Yu Wang (1)
Zhi-Ming Li (1)
Jia-Jia Huang (1)
Yi Xia (1)
Heng Li (2)
Ya-Jun Li (1)
Ying-Jie Zhu (1)
Wei Zhao (1)
Xi-Ya Xia (1)
Wen-Xiao Wei (1)
Hui-Qiang Huang (1)
Tong-Yu Lin (1)
Wen-Qi Jiang (1)
1. State Key Laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 Dong Feng Road East, Guangzhou, 510060, China
2. Emergency Department, Sun-Yat-sen Memorial Hospital, Guangzhou, China - ISSN：1423-0380
文摘
The standard treatment of primary testicular lymphoma (PTL) has not been well established. Our study aimed to evaluate the relationship between the prognostic factors and clinical outcomes of PTL. We retrospectively reviewed the clinical records of 43 PTL patients and included the 39 patients who were diagnosed with primary testicular diffuse large B cell lymphoma (DLBCL) for analysis of prognostic factors and assessment of treatment modalities. Cox regression analysis showed that poor ECOG performance status (PS, ?), infiltration of adjacent tissues (spermatic cord, epididymis, or scrotum), and bulky disease (tumor mass, >9?cm) were independent predictors of worse overall survival (OS) for primary testicular DLBCL. According to these three factors, the patients were divided into two groups. Rituximab was found to significantly prolong progression-free survival (PFS) in the low-risk group (P--.044) but not in the high-risk group (P--.748). And the combination therapy for CNS prophylaxis significantly prolonged the survival in the high-risk group (P--.005 for OS; P--.004 for PFS), but not in the low-risk group (P--.092 for OS; P--.191 for PFS). ECOG performance status, infiltration of adjacent tissues, and bulky disease are practical prognostic factors of survival in patients with primary testicular DLBCL. The addition of rituximab is more important for the patients without the prognostics factors, and the combination CNS prophylaxis is more significant for the patients with the prognostics factors.